SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE) Files An 8-K Other Events

Item 8.01.

As previously disclosed by Sorrento Therapeutics, Inc. (Sorrento)
in its Current Report on Form 8-K filed with the U.S. Securities
and Exchange Commission (the SEC) on November 8, 2016, as amended
by its Current Report on Form 8-K/A filed with the SEC on January
20, 2017 (the Amended Form 8-K), on November 8, 2016, Sorrento
entered into a Stock Purchase Agreement (the Purchase Agreement)
with Scilex Pharmaceuticals Inc. (Scilex) and a majority of the
stockholders of Scilex (the Scilex Stockholders) to which, on
November 8, 2016, Sorrento acquired from the Scilex Stockholders,
and the Scilex Stockholders sold to Sorrento, approximately 72%
of the outstanding capital stock of Scilex.

The Amended Form 8-K also provided the historical financial
statements of Scilex Pharmaceuticals Inc. and the pro forma
financial information of Sorrento required by Item 9.01 of Form
8-K.

The purpose of this Current Report on Form 8-K is to provide
additional pro forma financial information of Sorrento for the
year ended December 31, 2016.

(a) Financial Statements of Businesses Acquired.

None.

(b) Pro Forma Financial Information.

The unaudited pro forma condensed combined financial information
of Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc.
for the year ended December 31, 2016 is filed as Exhibit 99.1 to
this Current Report on Form 8-K and is incorporated by reference
herein.

(c) Shell Company Transactions.

None.

(d) Exhibits.

About SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE)

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.

SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE) Recent Trading Information

SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE) closed its last trading session 00.00 at 1.90 with 806,081 shares trading hands.